New drug fruquintinib under Real-World watch for tough colorectal cancer
NCT ID NCT06787105
First seen Apr 12, 2026 · Last updated Jun 13, 2026 · Updated 10 times
Summary
This study tracks 150 adults in Germany with metastatic colorectal cancer who are taking Fruquintinib after other treatments stopped working. Researchers will see how well the drug controls the cancer in real-life settings, including survival, side effects, and quality of life. The goal is to understand the drug's true benefit outside of strict clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Onkologische Schwerpunktpraxis
RECRUITINGHanover, Lower Saxony, 30161, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.